Q-omics provides the consensus-scored ADAD1 profile across patient tissues and cancer cell-line models. ADAD1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ADAD1 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, ADAD1 RNA expression shows 7,831 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KICH, and TGCT as cancer lineages where ADAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAD1 survival associations across molecular data types. ADAD1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAD1 RNA expression–survival associations across cancer types. High ADAD1 expression shows unfavorable associations in LIHC, BRCA, LGG, SCLC and KIRC, but favorable associations in OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ADAD1 RNA expression.
This table summarizes ADAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAD1 shows lower tumor expression in KICH and higher tumor expression in KIRC. The KICH box plot shows higher ADAD1 RNA expression in normal versus tumor tissue (log2 FC = −0.005, t-test p = .039).
This table shows molecular features associated with ADAD1 in patient tissues and cancer cell lines. In patient samples, ADAD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
